Knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated. Understanding the role biomarkers can play in this emerging treatment landscape has large implications, especially for companies seeking to launch new drugs and compete with the market leaders by positioning them in indications where they hopefully show higher response rates. Biomarkers are the best hope for streamlining trials in this way and to help secure favourable pricing ..........

You just need to REGISTER - its FREE - to read the rest of this article straight away.